Welcome to our dedicated page for Varex Imaging news (Ticker: VREX), a resource for investors and traders seeking the latest updates and insights on Varex Imaging stock.
Varex Imaging Corporation reports developments tied to its X-ray imaging component business, including X-ray tubes, digital detectors, connecting devices, imaging software and industrial X-ray systems. Company news commonly covers results from its Medical and Industrial segments, demand trends in CT products, cargo security systems and photon counting detectors, and updates for products used by global OEM manufacturers in medical, industrial and security imaging applications.
Recurring announcements also include earnings releases and conference calls, investor conference participation, and capital-structure actions such as the refinancing of secured debt and redemption of senior secured notes.
Varex Imaging (Nasdaq: VREX) reported unaudited Q3 FY26 revenues of $210.5 million, up 4% year over year, with Medical at $134.0 million and Industrial at $76.5 million. GAAP gross margin was about 36% and GAAP operating margin about 11%. GAAP diluted EPS was $0.37, while non-GAAP EPS was $0.31, compared with $0.13 a year earlier.
During the quarter, Varex received $17 million in U.S. Customs refunds for previously paid IEEPA tariffs and recorded a $7 million revenue reduction for expected customer reimbursements, increasing gross profit by roughly $10 million. Non-GAAP gross margin rose to 36.7% from 33.5%. Operating cash flow was $21 million. Cash, cash equivalents, and marketable securities totaled $99 million, down from $155 million at FY25 year-end, mainly due to earlier debt redemption/refinancing and higher inventory.
In connection with its announced transaction with Teledyne Technologies, Varex cancelled its Q3 earnings call and is not providing financial guidance.
Teledyne Technologies (NYSE:TDY) and Varex Imaging (NASDAQ:VREX) have signed a definitive agreement for Teledyne to acquire all outstanding Varex common shares for $18.90 per share in cash, implying an aggregate transaction value of about $1.1 billion, including equity awards and net debt as of April 3, 2026.
The deal was unanimously approved by both companies’ boards and is expected to close in early 2027, subject to regulatory approvals and Varex stockholder approval. Varex supplies X-ray tubes, digital X-ray detectors, photon counting detectors, high-voltage interconnects and imaging software for medical, industrial, security and inspection markets. Teledyne highlighted that Varex’s X-ray tubes and photon counting detectors complement Teledyne’s existing detector and vacuum electronics portfolio with minimal product overlap.
Varex Imaging (Nasdaq: VREX) will release its unaudited financial results for the third quarter of fiscal year 2026 after the close of regular trading on Monday, August 10, 2026. A conference call to discuss the results will follow at 3:00 p.m. Mountain Time.
Investors can join via webcast on the Varex investor relations webpage or by phone at 877-524-8416 (U.S.) and 412-902-1028 (non-U.S.). A replay will be available from August 10–24, 2026 at 877-660-6853 (U.S.) and 201-612-7415 (non-U.S.) using access code 13761894, with an archived webcast on the company’s site.
Varex Imaging (Nasdaq: VREX) announced that management will present at the Jefferies Global Healthcare Conference in New York.
The fireside chat is scheduled for Wednesday, June 3, 2026 at 3:10 pm ET and will be available via webcast on the company’s website.
Varex (Nasdaq: VREX) reported Q2 fiscal 2026 results: revenue $216M, GAAP gross margin 34%, non-GAAP gross margin 34%, GAAP operating margin 7%, non-GAAP operating margin 9%, GAAP loss $0.19 per share and non-GAAP income $0.21 per share.
Cash, cash equivalents and marketable securities were $88M at quarter end (down from $155M). Full‑year revenue guidance is $860M–$880M with non‑GAAP EPS of $0.80–$1.00. Q3 revenue guidance is $210M–$225M and non‑GAAP EPS $0.15–$0.30.
Varex (Nasdaq: VREX) will report unaudited fiscal 2026 second quarter results after market close on May 7, 2026, followed by a conference call at 3:00 pm Mountain Time. The call will be webcast live and archived on the company investor website.
Replay access runs from May 7 through May 21, 2026, with domestic and international dial‑in numbers and a replay access code available.
Varex Imaging (Nasdaq: VREX) closed a new secured $490 million Credit Facility dated March 13, 2026, maturing March 13, 2031, composed of a $350M term loan, $100M revolver and $40M delayed draw term loan.
The company redeemed $368M of 7.875% senior secured notes using about $42M cash and entered an interest rate swap fixing SOFR at 3.65%, expected to cut annualized cash interest expense by more than $7M.
Varex (Nasdaq: VREX) management will present at two upcoming investor conferences in March 2026: Oppenheimer’s 36th Annual Healthcare, MedTech & Services Virtual Conference and the Sidoti Small Cap Virtual Conference. Webcasts are available via the listed conference links or on Varex's investor website.
Varex Imaging (Nasdaq: VREX) issued a conditional full redemption notice for all outstanding 7.875% senior secured notes due Oct 15, 2027, with a Redemption Date of March 16, 2026 subject to a new credit facility closing.
The outstanding principal is $368,000,000. The redemption price equals 101.969% plus accrued interest, totaling $1,052.72125 per $1,000 principal. The Company intends to fund the payment with proceeds of the New Financing and cash on hand; the redemption is conditional on the Financing Condition.
Varex (Nasdaq: VREX) reported Q1 FY2026 revenue of $210 million, up 5% year-over-year, with Medical at $145 million and Industrial at $65 million. GAAP net income was $0.05 per diluted share; non-GAAP EPS was $0.19. Cash outflow from operations was $16 million; cash and marketable securities totaled $126 million. Q2 guidance: revenue $210–225 million and non-GAAP EPS $0.15–0.25.